Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer
Ontology highlight
ABSTRACT: The present project will follow our previous phaseⅡ study of FOLFOX regimens for the treatment of stage Ⅳ colorectal cancer. We will recruit at least 200 patients for this study. The selection of patients will be based on rigorous eligibility criteria. The patients will be allocated based on the expression of each molecular marker (MSI, TS, DPD, MVD and EGFR) and the implementation of chemotherapy. For example, in the examination for the clinical implications of EGFR, the patients will be classified into four groups: EGFR(+) chemotherapy(+); EGFR(+) chemotherapy(-); EGFR(-) chemotherapy(+); EGFR(-) chemotherapy(-). Base on the analysis of this 2×2 table, we will clarify the prognostic significance of a specific molecular marker is due to whether the specific molecular marker predicts biological invasiveness and/or chemosensitivity. We believe the present study will have the following significance: (1)To further clarify the mechanisms for the carcinogenesis and progression of CRC; (2)To facilitate the development of novel chemotherapeutic agents; and (3) To gain the experience for the practice of evidence-based medicine.
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2017518 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA